USSTOCK.TODAY
Market Closed
Log in Sign up

Bioline Rx Ltd ADR(BLRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

BLRX
BLRX
Bioline Rx Ltd ADR
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$1.06
-0.09 ▼ -7.83%
Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$1.06
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -1.82Insider Own ⓘ 0.56%Shs Outstand ⓘ 5.0MPerf Week ⓘ -21.48%
Market Cap ⓘ 0.01BForward P/E ⓘ -EPS next Y ⓘ 19.75%Insider Trans ⓘ -Shs Float ⓘ 5.0MPerf Month ⓘ -49.76%
Enterprise Value ⓘ 0.00BPEG ⓘ -EPS next Q ⓘ -0.39Inst Own ⓘ 11.4%Short Float ⓘ 2.76%Perf Quarter ⓘ -62.28%
Income ⓘ -0.01BP/S ⓘ 3.77EPS this Y ⓘ -Inst Trans ⓘ 29.45%Short Ratio ⓘ 6.16Perf Half Y ⓘ -62.94%
Sales ⓘ 0.00BP/B ⓘ 0.34EPS next 5Y ⓘ -ROA ⓘ -20.94%Short Interest ⓘ 0.14MPerf YTD ⓘ -61.73%
Book/sh ⓘ 3.15P/C ⓘ 0.4EPS past 3/5Y ⓘ 75.3% 66.78%ROE ⓘ -47.48%52W High ⓘ -73.16% ($3.95)Perf Year ⓘ -68.17%
Cash/sh ⓘ 2.63P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -47.39%52W Low ⓘ 0.95% ($1.05)Perf 3Y ⓘ -98.43%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 55.29%Gross Margin ⓘ 55.01%Volatility(W/M) ⓘ 17% 9.8%Perf 5Y ⓘ -99%
Dividend TTM ⓘ -EV/Sales ⓘ 2.13Sales Y/Y TTM ⓘ -91.94%Oper. Margin ⓘ -875.98%ATR (14) ⓘ 0.16Perf 10Y ⓘ -99.85%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 1.04EPS Q/Q ⓘ 31.62%Profit Margin ⓘ -574.29%RSI (14) ⓘ 12.84Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 1.2Sales Q/Q ⓘ -3.7%SMA20 ⓘ -35.79% ($1.65)Beta ⓘ 1.74Target Price ⓘ $22
Payout ⓘ -Debt/Eq ⓘ 0.58Earnings ⓘ 2026/11/23SMA50 ⓘ -48.3% ($2.05)Rel Volume ⓘ 1.45Prev Close ⓘ $1.15
Employees ⓘ 24LT Debt/Eq ⓘ 0.23EPS/Sales Surpr. ⓘ - -41.2%SMA200 ⓘ -59.76% ($2.63)Avg Volume(3M) ⓘ 0.02MPrice ⓘ $1.06
IPO ⓘ 2011/7/25Option/Short ⓘ Yes/YesTrades ⓘ 154Volume ⓘ 32,239Change ⓘ -7.83%
Company
BLRX BLRXBioline Rx Ltd ADR | NASD | Biotechnology Deep dive

🧬 BiolineRx () is an Israel-based oncology-focused biotech company with a track record of securing FDA approval for its CXCR4 inhibitor motixafortide (brand name APHEXDA®) as a stem cell mobilizer for multiple myeloma. The company is currently in a combined clinical and commercialization stage, generating royalty revenue from global partnerships for the marketed APHEXDA while simultaneously advancing its clinical pipeline targeting pancreatic cancer (PDAC) and glioblastoma (motixafortide PDAC Phase 2b, GLIX1).

Quote

Over the past 1 year, on the lower side

73% below its 1-year high.

Now $1.06
52w low$1.0552w high$3.95
52W Range0%
Volume ⓘ 32,239

Traded more than usual. That is 145% of its average volume.

Upcoming events

Next earnings report: November 23

3 days to go.

Earnings dateNovember 23
C
Overall · average, with some caution
We judged 6 of the 8 questions below. 1 rate excellent and 2 need caution.
No data for earnings, dividends, or not applicable.
Peer comparison Biotechnology

It ranks #537 of 598 in the industry

Based on market cap of $5M.

FAQ

FAQ

What kind of company is BLRX?

BLRX belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of BLRX?

The market cap of BLRX is approximately $5M, ranking 5,550 within its sector.

What is the 52-week high and low for BLRX?

BLRX has recorded a 52-week high of $3.95 and a low of $1.05.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels